MDXG · Mimedx Group, Inc. · Executive Compensation
10 customers — 22% of revenue (the year ended December 31, 2025)
“For the years ended December 31, 2025, 2024, and 2023, our top ten customers accounted for 22%, 20% and 20%, respectively, of our net sales”
Key customers — 1% of revenue (the year ended December 31, 2025)
“net sales to all U.S. government accounts comprised approximately 1%, 1% and 2%, respectively, of our net sales.”
10 customers — 20% of revenue (the year ended December 31, 2024)
“For the years ended December 31, 2025, 2024, and 2023, our top ten customers accounted for 22%, 20% and 20%, respectively, of our net sales”
Key customers — 1% of revenue (the year ended December 31, 2024)
“net sales to all U.S. government accounts comprised approximately 1%, 1% and 2%, respectively, of our net sales.”
10 customers — 20% of revenue (the year ended December 31, 2023)
“For the years ended December 31, 2025, 2024, and 2023, our top ten customers accounted for 22%, 20% and 20%, respectively, of our net sales”
Key customers — 2% of revenue (the year ended December 31, 2023)
“net sales to all U.S. government accounts comprised approximately 1%, 1% and 2%, respectively, of our net sales.”
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
|
Ricci Whitlow
“Ms. Whitlow’s departure was not a result of a disagreement with the Company.”
|
Chief Operating Officer | Terminated | 2026-04-16 |
| Dorothy E. Puhy | member of the Board of Directors | Appointed | 2024-03-04 |
| Tiffany P. Olson | member of the Board of Directors | Appointed | 2024-03-04 |
|
William Phelan
“Neither the decision to combine roles nor Mr. Phelan’s decision to retire is the result of any dispute or disagreement.”
|
Chief Accounting Officer | Retired | 2023-09-05 |
| Pete Carlson | Chief Financial Officer | Resigned | 2023-07-05 |
| Doug Rice | Chief Financial Officer | Appointed | 2023-07-05 |
| Dr. Robert Stein | President of the Company's Regenerative Medicine business unit | Terminated | 2023-06-20 |
| Peter M. Carlson | Chief Financial Officer | Resigned | 2023-03-24 |
| Joseph H. Capper | Board of Directors | Appointed | 2023-01-30 |
| Joseph H. Capper | Chief Executive Officer | Appointed | 2023-01-30 |
| Ricci S. Whitlow | Executive Vice President and Chief Operating Officer | Appointed | 2023-01-03 |
|
Dr. Rohit Kashyap
“Dr. Kashyap's resignation was not the result of any dispute or disagreement with the Company or its Board of Directors.”
|
President, Wound Care and Surgical | Resigned | 2022-12-16 |
|
Timothy R. Wright
“Employee represents that he has no disagreements with the Company on any matter relating to the Company’s operations, policies or practices.”
|
Chief Executive Officer | Terminated | 2022-09-16 |
| K. Todd Newton | Interim Chief Executive Officer | Appointed | 2022-09-16 |
| Timothy R. Wright | Chief Executive Officer | Terminated | 2022-09-06 |
| Timothy R. Wright | member of the board of directors | Terminated | 2022-09-06 |
| K. Todd Newton | interim Chief Executive Officer | Appointed | 2022-09-06 |
Leadership
- K. Todd Newton CEO, Board Member
- Ricci S. Whitlow COO
- William L. Phelan Chief Accounting Officer
- Dorothy E. Puhy Board Member
- Dorothy Puhy Board Member
- James L. Bierman Board Member
- Joseph H. Capper Board Member
- Martin P. Sutter Board Member
- Tiffany Olson Board Member
- Tiffany P. Olson Board Member
- Todd Newton Board Member
- William A. Hawkins Board Member
- William A. Hawkins, III Board Member